test-nav-cat
Jun
21

Imaging biomarkers in NAFLD: Could they avoid liver biopsy?

There is a need for new biomarkers that allow the detection and...

Jun
21

Immunotherapy-treated HCC: NASH limits anti-tumour surveillance

Immunotherapy has been approved for treating hepatocellular carcinoma (HCC), but biomarker-based stratification...

Jun
21

Rising awareness on NAFLD progression by influencing threat perceptions

Semi-structured interviews with T2DM patients were conducted by M. Alemany-Pages et al....

Jun
16

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

Prof. Rautou, France, discusses a critical component of the diagnosis and management...

Jun
16

NAFLD and risk factors: accuracy and limitations of the ICD-10-Australian Modification

K. L. Hayward et al. conducted a retrospective audit to explore the...

Jun
16

Awareness of suffering of advanced liver disease in patients with T2D is remarkably low

The aim of the present population-based cross-sectional study is to estimate the...

The PanNASH initiative is supported by
logo (1)